Product Pipeline

Anumigilimab Anti-G-CSFR mAb (SCD)

CSL040 Complement R1 Inhibitor

A recombinant glycoprotein which inhibits the classical, lectin and alternative Complement pathways for the potential treatment of acute indications involving Complement‐mediated tissue damage and inflammation.

CSL405 Cell-based Influenza (H2N3) Vaccine

For protection against Pandemic Influenza A (H2N3)

CSL406 sa-mRNA Influenza (H5N1) Vaccine

For protection against Pandemic Influenza A (H5N1).

CSL400 (TIV) sa-mRNA Trivalent Influenza Vaccine

LASN01 Anti-IL-11R mAb (IPF, TED)

Humanized recombinant monoclonal antibody targeting interleukin-11 (IL-11) for the potential treatment of Idiopathic Pulmonary Fibrosis (IPF) and Thyroid Eye Disease (TED).
*Licensed to Lassen Therapeutics.

Horizon 2 Ig Yield

CSL787 Nebulised Ig

Human plasma-derived immunoglobulin for administration via a nebulizer for the potential prevention of chronic respiratory tract infections and progression of chronic lung disease such as Non-Cystic Fibrosis Bronchiectasis (NCFB).

Hemopexin (VOC in SCD)

Plasma-derived hemopexin for potential treatment of acute Vascular Occlusive Crisis (VOC) in Sickle Cell Disease (SCD) patients.

Vamifeport Ferroportin inhibitor (HH)

CSL301 Anti-α2AP mAb (sPE)*

Anti-α2-antiplasmin monoclonal antibody, which is being developed to dissolve thrombi that cause serious conditions such as submassive pulmonary embolism (sPE) and acute ischemic stroke (AIS).

CSL525 (SNF472) Calcification inhibitor (CUA-ESKD)

Calcification inhibitor for treatment of calcific uremic arteriolopathy (CUA) in patients with end-stage kidney disease (ESKD).

Eblasakimab (CSL334) Anti-IL-13R mAb (AD)

Monoclonal antibody targeting IL-13Rα1 for the treatment of atopic dermatitis (AD) and asthma.
*Licensed to ASLAN Pharmaceuticals.

HIZENTRA^® (SCIg) 20% Liquid
(CLL)

HIZENTRA^® (SClg) 20% Liquid (POTS)

20% subcutaneous immunoglobulin for the treatment and long-term maintenance therapy of adults with Dermatomyositis (DM).

RiaSTAP^® Fibrinogen Concentrate (AFD)

Clazakizumab Anti-IL-6 mAb
(ESKD)

Humanized recombinant monoclonal antibody targeting interleukin-6 (IL-6) for the potential treatment of end stage kidney disease (ESKD) in patients undergoing dialysis .

CSL964 Alpha 1 Antitrypsin (Treatment of aGvHD)*

Treatment of steroid refractory, acute Graft-versus-Host Disease (aGvHD) in high-risk patients receiving an allogenic hematopoietic stem cell transplant (HSCT) using Alpha-1 Antitrypsin (AAT).

CSL964 Alpha 1 Antitrypsin (Prevention of aGvHD)

Prevention of acute Graft-versus-Host Disease (aGvHD) in high-risk patients receiving an allogenic hematopoietic stem cell transplant (HSCT) using Alpha-1 Antitrypsin (AAT).

FLUAD^® Trivalent Efficacy Adjuvanted Egg-based Influenza Vaccine

CSL403 (aTIVc) Adjuvanted Cell-based Trivalent Influenza Vaccine

Trivalent Seasonal Influenza Vaccine (Adjuvanted; Cell-based). High dose vaccine offering protection against different influenza virus strains.

HIZENTRA^® (SCIg) 20% Liquid

20% subcutaneous immunoglobulin for the treatment and long-term maintenance therapy of adults with Dermatomyositis (DM).

PRIVIGEN^® (IVIg) 10% Liquid

10% intravenous immunoglobulin.

ZEMAIRA^®/RESPREEZA^® Alpha 1 Antitrypsin

Human Alpha 1 Antitrypsin (AAT) (Plasma); To slow the progression of emphysema caused by Alpha 1 Antitrypsin Deficiency (AATD).

HAEGARDA^® C1 Inhibitor (HAE)

Subcutaneous C1 Esterase Inhibitor (C1-INH) (Plasma), prophylaxis therapy for Hereditary Angioedema (HAE) attacks.

Garadacimab Anti-FXIIa mAb (HAE)

Humanised anti-factor XIIa monoclonal antibody for the potential treatment of Hereditary Angioedema (HAE) by subcutaneous administration.

AFSTYLA^® rFVIII (Haem A)

Novel, recombinant factor VIII product for the treatment of adults and children with hemophilia A.

IDELVION^® rFIX-FP (Haem B)

Novel, long-acting recombinant factor IX product for the treatment of hemophilia B.

HEMGENIX^® (Haem B)

Adeno-associated virus vector-based gene therapy indicated for treatment of adults with Hemophilia B (congenital Factor IX deficiency).

FILSPARI^® (Sparsentan) Dual ET_A
& AT₁ antagonist (IgAN)*

Oral, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist (DEARA) with high selectivity for the ETAR and AT1R for treatment of immunoglobulin A nephropathy (IgAN).

KORSUVA^®/KAPRUVIA^® KOR. agonist (CKD-aP)*

Difelikefalin - a kappa-opioid receptor (KOR) agonist for treatment of moderate-to-severe pruritus associated with CKD in adult patients on haemodialysis.

RAYALDEE^® Oral ext. release calcifediol (SHPT)*

Orally administered, prolonged-release formulation of calcifediol for the treatment of secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency or deficiency.

TAVNEOS^® Oral C5a receptor inhibitor (AAV)*

Orally administered, highly potent and selective inhibitor of C5aR1 (complement C5a receptor 1) for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (ANCA)-associated vasculitis (AAV).

VELPHORO^® Sucroferric oxyhydroxide (Serum P control in CKD)

A non-calcium, iron-based phosphate binder used for the control of serum phosphorus levels in adults with chronic kidney disease (CKD) on haemodialysis or peritoneal dialysis.

VELTASSA^® Oral potassium binder (HK)

A non-absorbed, oral potassium binder for the treatment of hyperkalemia.

AUDENZ ^®/CELLDEMIC^® Adjuvanted Cell-based Monovalent Influenza A (H5N1) Vaccine

FOCLIVIA^®/AFLUNOV^® Adjuvanted Egg-based Influenza A (H5N1) Vaccine

Pre-pandemic, egg-based vaccine combined with CSL Seqirus' proprietary adjuvant, MF59® (an additive that acts to strengthen the immune response to vaccination), to protect against influenza A (H5N1) - the 'bird-flu' strain.

FLUAD^® Trivalent Adjuvanted Egg-based Influenza Vaccine

FLUCELVAX^® Trivalent Cell-based Influenza Vaccine

Seasonal cell culture-based, quadrivalent influenza vaccine offering protection against four different strains for use in children 6 months of age and older.

KOSTAIVE^® sa-mRNA Vaccine (COVID)

Novel seasonal COVID-19 booster vaccine using self-amplifying platform. The technology offers the potential for higher efficacy and longer duration and breadth of protection at lower doses of mRNA.